Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein.

Int J Antimicrob Agents

Monash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Victoria, Australia. Electronic address:

Published: August 2020

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic is a global public health emergency, and new therapeutics are needed. This article reports the potential drug target and mechanism of action of Arbidol (umifenovir) to treat coronavirus disease 2019 (COVID-19). Molecular dynamics and structural analysis were used to show how Arbidol targets the SARS-CoV-2 spike glycoprotein and impedes its trimerization, which is key for host cell adhesion and hijacking, indicating the potential of Arbidol to treat COVID-19. It is hoped that knowledge of the potential drug target and mechanism of action of Arbidol will help in the development of new therapeutics for SARS-CoV-2.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187825PMC
http://dx.doi.org/10.1016/j.ijantimicag.2020.105998DOI Listing

Publication Analysis

Top Keywords

spike glycoprotein
8
potential drug
8
drug target
8
target mechanism
8
mechanism action
8
action arbidol
8
arbidol
5
arbidol potential
4
potential antiviral
4
antiviral drug
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!